We have studied the estrogenic regulation and the potential autocrine role of transforming growth factor a (TGFa) in the human breast cancer cell line MCF-7. A biologically active apparent mol wt 30 k TGFa was identified by gel filtration chromatography in medium conditioned by MCF-7 breast cancer cells. We previously reported induction of TGFa levels in medium by 170-estradiol. We now report correlated increases in TGFa mRNA, by Northern and slot blot analysis, after estrogen treatment of MCF-7 cells in vitro. In vivo experiments confirmed these data: estrogen withdrawal from MCF-7 tumor-bearing nude mice resulted in a decline in tumor size and TGFa mRNA levels. To explore the functional significance of TGFa in MCF-7 cells, anti-TGFa antibody was added to MCF-7 soft agar cloning assays. Inhibition of MCF-7 growth resulted, supporting an autocrine role for TGFa. Further experiments using an anti-EGF receptor antibody expanded this data, demonstrating inhibition of estrogen-stimulated monolayer MCF-7 cell growth. Examining the generality of TGFa expression, 4.8 kilobase TGFa mRNAs were seen in three other human breast cancer cell lines, MDA-MB-231, ZR 75B, and T47D. Expression of TGFa mRNA was detected in 70% of
INTRODUCTION
Breast cancer is one of a small number of malignancies in which both genesis and growth have been linked to hormonal factors. About one-third of all metastatic human breast cancers are responsive to endocrine therapies (1) . Hormone withdrawal in these estrogenresponsive cancers results in regression but rarely complete resolution of the disease. Study of these estrogenresponsive tumors has been facilitated by the existence of estrogen-receptor positive human breast cancer cell lines which respond to estrogen by increased cell growth in vitro and are dependent upon estrogen for tumor formation in nude mice. However, the mechanism of estrogen action in these cell lines, in human primary breast tumors, and in normal breast epithelium is incom-543 pletely understood. We have postulated that estrogen may act by inducing the elaboration of secreted factors which promote the growth of cells.
We have previously reported the regulation by estrogen of the mitogenic polypeptide, transforming growth factor a (TGFa), in several human breast cancer cell lines (2, 3) . TGFa was originally characterized by its ability, in combination with transforming growth factor /S, to induce the anchorage-independent growth of a normal fibroblast cell line, the NRK cell line (4, 5) . Its potential involvement in malignant transformation was underscored by its presence in a variety of human tumors, and in cell lines transformed by both chemical carcinogens and viral oncogenes (6) (7) (8) (9) (10) (11) (12) , but the precise role which TGFa plays in human neoplasia has never been established.
Both TGFa and its functional homologue, epidermal growth factor (EGF), appear to act through a common cell surface receptor, generally termed the EGF receptor (13, 14) . They share many biological activities including stimulation of cell growth (9, 15, 16) . Induction of epithelial cell colony formation by TGFa has been reported in a limited number of studies (17) (18) (19) . EGF has been shown to stimulate the growth of three human breast cancer cell lines in vitro, including the MCF-7 cell line (16, (20) (21) (22) . Further, EGF has been shown to stimulate MCF-7 tumor formation in nude mice in the absence of estrogen (23) and has been directly implicated in the induction of mouse mammary tumorigenesis (24) .
Because human breast cancer cell lines and human breast tumors contain EGF receptors (25) (26) (27) (28) , an autocrine pathway can be proposed for TGFa in human breast cancer cells. According to this hypothesis, cells secrete mitogenic polypeptides which act through their own cell surface receptors to stimulate growth (29) . Since human breast cancer cells contain the EGF/TGFa receptor and respond to EGF by increased growth, demonstration of TGFa production by these cells suggests that an autocrine loop may be operative in breast cancer cell growth. Further, regulation of TGFa production in estrogen-responsive cell lines implies that this autocrine pathway for cellular growth is hormonally regulated.
Purified human TGFa is a 50-amino acid peptide with a mol wt of 5600, which is homologous to EGF (6, 12) . A 17-19 kDa precursor protein has been identified as a biologically active form of TGFa which is equipotent with the mature polypeptide (30) . A cDNA clone encoding a predicted 160-amino acid precursor recognizes a 4.8 kb mRNA species in Northern blots (31) (32) (33) .
Tests of the autocrine hypothesis using antibodies to interfere with TGFa action have had variable results. Antisera directed against the EGF receptor were shown to block EGF/TGFa-induced anchorage-independent colony formation by normal rat fibroblasts (34) . However, in a TGFa-secreting melanoma cell line, it was shown that a monoclonal antibody which blocked EGF and TGFa binding to the EGF receptor failed to block growth or anchorage-independent colony formation (35) . It was noted, though, that these cells had no detectable EGF receptors on their cell surface. In a third study, three monoclonal antibodies directed against the EGF receptor were found to block tumor formation by two of four human tumor cell lines in nude mice (36) .
TGFa protein has been identified in conditioned media from a number of breast cancer cell lines, and in extracts of primary breast tumors (2, 3, 7, 8) . TGFa is induced by estrogen 2-to 8-fold in MCF-7 cells. This induction may account for a portion of the mitogenic and tumor promoting effects of estrogen. We now report further studies of TGFa expression in primary human breast tumors and four human breast cancer cell lines. We sought to determine whether the observed induction of TGFa-like activity by estrogen in vitro in MCF-7 cells could be correlated with induction of TGFa mRNA, whether TGFa mRNA regulation could be demonstrated in vivo in MCF-7 tumors, whether we could provide evidence for an autocrine role for TGFa, and whether our observations of TGFa expression in human breast cancer cell lines could be extended to primary human breast tumors.
RESULTS

Production of Authentic TGFa by MCF-7 Cells
Initial experiments using gel filtration chromatography suggested the presence of a 30 k apparent mol wt TGFa activity in conditioned medium from MCF-7 cells (2). To determine whether this activity was recognized by antibodies developed against low mol wt TGFa, conditioned medium was acid treated and fractionated in 1 M acetic acid on a Bio-Gel P100 column. Two principle peaks of activity were detected, one with apparent mol wt of 30 k, and the other at 7 k (Fig. 1) . Each of these peaks contained TGFa activity as detected by TGFa RIA, NRK colony formation, and EGF receptor competition. The activities measured by EGF receptor competition and TGFa RIA were comparable on a molar basis. Confirmation of the existence of a secreted high mol wt form of TGFa in MCF-7 cells was provided by the detection of multiple immunoreactive species near 30 k after immunoprecipitation of [ 35 
S]
cysteine labeled conditioned medium from MCF-7 cells (Fig. 2) . Multiple bands of immunoprecipitated material were seen at approximately 30 k after sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. These bands were absent when the immunoprecipitation was performed in the presence of excess unlabeled TGFa. These results confirm our initial observations and show that a biologically active high mol wt immunoreactive TGFa is synthesized by MCF-7 cells.
Induction of TGFa Activity and TGFa mRNA by Estrogen in MCF-7 Human Breast Cancer Cells
To determine whether the induction of TGFa by estrogen occurred in conjunction with alterations in TGFa Four liters of serum-free conditioned medium from cells previously grown in 10% FBS were concentrated and then acidified by dialysis against 1 M acetic acid. The sample was applied to a 2.6 x 70-cm Bio-Gel P100 column equilibrated with 1 M acetic acid. Seven-milliliter fractions were collected, lyophilized, and resuspended in 1 ml 4 rriM HCI for assay. mRNA levels, MCF-7 cells were grown with and without addition of 10~8 M 17^-estradiol for 48 h in medium depleted of estrogen. Three paired experiments were done with cells grown in serum-containing medium used for RNA preparation, and cells grown in serum-free medium used for conditioned medium collections. We again demonstrated induction of TGFa activity by estrogen in medium conditioned by these cells, greater than 2-fold in both dose-response curves for EGF/ TGFa-induced NRK colony-forming activity and in EGF radioreceptor competing activity. Conditioned media from three separate experiments contained 0.102 ± 0.014 pg//ig DNA EGF receptor competing activity after estrogen treatment for 48 h, significantly differing from the control media containing 0.044 ± 0.024 pg//*g DNA (P < 0.005). Total RNA from estrogen-treated and control cells was purified and directly applied to nitrocellulose filters using a slot blot apparatus. As shown in Fig. 3A , there was 2.6-fold induction of the TGFa message by estrogen in MCF-7 cells. Additionally, both total and poly(A) + selected RNA were examined by Northern analysis (Fig. 3B) . The previously reported 4.8 kb message was easily identified in Northern transfers containing both total RNA (data not shown) and poly(A) + selected RNA, and was increased 2-to 3-fold by estrogen treatment. Additionally, a 1.6 kb message 10-fold less abundant and not visible on photographs of MCF-7 lanes was faintly detected in poly(A) + selected RNA. S-Cysteine Labeled MCF-7 Cells Immunoprecipitations were carried out in the presence (+) or absence of (-) of 250 ng human TGFa (54) . The immunoprecipitates were washed and bound material eluted from the Sepharose by incubation with 1 ml 1 M acetic acid for 30 min at 60 C. The material was lyophilized and run on a 15% discontinuous SDS-polyacrylamide gel, incubated with EnHance (New Nuclear Corp.) dried, and exposed to Kodak XOmat for 4 weeks at -7 0 C. Similar results were obtained with a different antibody in two subsequent immunoprecipitations.
Control hybridizations with jS-actin revealed no differences in RNA loading in these experiments.
Dose-response and time course studies of estrogen induction of TGFa mRNA were performed. A 2-fold estrogen stimulation of TGFa mRNA was seen as early as 6 h after estrogen treatment, and remained stable over 6 days of estrogen treatment (data not shown). 
In vivo Regulation of TGFa mRNA by Estrogen in MCF-7 Xenografts
Growth of MCF-7 tumors in nude mice is dependent upon the presence of estrogen. To determine whether induction of TGFa mRNA by estrogen may occur during tumor formation in vivo, TGFa mRNA levels were examined in MCF-7 tumor xenografts grown in female nude mice implanted with estrogen pellets. No tumors formed in animals without estrogen pellets. Tumorbearing animals were killed, or the estrogen pellets were removed, 3 weeks after injection of tumor cells. Tumors were subsequently removed at varying time intervals, and the RNA purified, poly(A) + enriched and analyzed by Northern analysis with a human TGFa cDNA probe. The levels of TGFa mRNA declined with increasing time after estrogen withdrawal ( effect was specific for the 4.8 kb TGFa mRNA since there was no decrease in the 2.1 kb 0-actin mRNA levels after estrogen withdrawal. These results confirm the regulation by estrogen of TGFa and extend that observation to an in vivo setting.
Inhibition of MCF-7 Anchorage-Independent Growth by Antihuman TGFa Antibody
The effect of a polyclonal anti-TGFa antibody on the anchorage-independent growth of MCF-7 cells was studied to determine whether TGFa could be functioning as an autocrine growth factor for MCF-7 cells. As shown in Table 1 
Inhibition of Estrogen-stimulated MCF-7 Anchorage-Dependent Growth by Anti-EGF Receptor Antibody
We also sought to determine whether interference with a TGFa autocrine growth loop could reverse the estrogen stimulation of MCF-7 cell growth after anchoragedependent culture. A mouse anti-EGF receptor monoclonal antibody previously shown to block binding of EGF to its receptor (35) was added to cells grown in the presence or absence of estrogen. These experiments were performed on cells grown in monolayer cultures because the effects of estrogen on MCF-7 cell growth are most easily demonstrable under these culture conditions. As shown in Table 2 , addition of 10 ng/ ml/day anti-EGF receptor antibody inhibited estrogenstimulated cell growth after 5 days of treatment but did not inhibit MCF-7 cells growing without estrogen. Control mouse IgG inhibited neither estrogen-treated or control MCF-7 cell growth. The effect of the anti-EGF receptor antibody was significant during the first 5 days of treatment, but not after the longer 10-day interval.
To determine whether the failure of the EGF receptor antibody to significantly inhibit growth after longer treatment intervals was simply due to effects of cell density, MCF-7 cells were plated in Exp 3 to achieve a comparable density at day 5 to that at day 10 in Exps 1 and 2. Anti-EGF receptor antibody again inhibited estrogen-induced proliferation, suggesting that TGFa mediated growth as occurring at the higher cell density. The results in Table 2 are consistent with the hypothesis that estrogen stimulation of MCF-7 cell growth over a 5-day treatment interval depends upon induction of a TGFa-mediated autocrine pathway. After longer estrogen treatment intervals, and in the absence of estrogen, additional growth factors or other mechanisms may perform roles in regulating MCF-7 cell growth.
Expression of TGFa mRNA in Human Breast Cancer Cell Lines
Four additional human breast cancer cell lines in which we had previously studied TGFa activities (2, 3) were also examined for TGFa mRNA expression. As shown in Fig. 6 , poly(A) + enriched mRNA analyzed on formaldehyde-agarose gels demonstrated a 4.8 kb mRNA for TGFa in the T47D, ZR-75-1, and MDA-MB-231 cell lines. Levels of TGFa mRNA expressed by T47D and ZR-75-1 cells were lower than those observed in the MDA-MB-231 cells, an estrogen unresponsive cell line.
In the MDA-MB-231 cell line, the 4.8 kb mRNA was readily identified and the 1.6 kb message faintly detected in MCF-7 cells was also observed. Expression of TGFa mRNA by the Hs578T cell line was not detectable after Northern analysis with the TGFa riboprobe. Thus, levels of TGFa mRNA correlated well with levels of secreted biologically active TGFa previously reported. It is of interest that the estrogen-receptor negative Hs578T cell line is a carcinosarcoma, and thus has a histology (and possibly origin) distinct from the other epithelial breast cancer cell lines studied (37) .
Range of Expression of TGFa mRNA in Primary Human Breast Tumors
Since TGFa mRNA is produced in varying levels by several breast cancer cell lines, we sought to learn whether similar variations could be found in primary two tumors expressing the most TGFa mRNA. By densitometric scanning, the 1.6 kb TGFa mRNA was 4-to 10-fold less intense than the 4.8 kb TGFa mRNA. These results confirm broad expression of TGFa mRNA in human tumors, show that expression is not directly related to hormone-receptor content, and demonstrate that the previously unreported 1.6 kb TGFa mRNA is present in human tumor tissue.
DISCUSSION
human breast tumors and whether such variations could be correlated with estrogen receptor status. Both total and poly(A) + selected mRNA from 40 human breast tumors were examined. RNA from the Hs578T cell line was included as a negative control. Fifteen representative samples of the 40 examined on slot blots are seen in Fig. 7 . The first two columns (samples a-h) include estrogen-receptor positive tumors, while samples from estrogen receptor negative tumors are shown in the third column (samples i-o). For comparison, a Northern blot including nine of these is shown in Fig. 8 . Total RNA contained detectable levels of TGFa mRNA in 70% of the 40 samples, and a few tumors showed very high TGFa mRNA levels. As shown in Table 3 , there was no correlation between the estrogen or progesterone receptor status of the tumor and TGFa mRNA expression.
Northern analysis of poly(A) + selected mRNA from 10 human breast tumors demonstrates the expression of the expected 4.8 kb TGFa mRNA in seven of these tumors (Fig. 9) . The 1.6 kb TGFa mRNA species observed in the breast cancer cell lines is also seen in the We have studied the expression of TGFa mRNA in human breast cancer cell lines and in primary human breast tumors. These studies demonstrate that TGFa mRNA is commonly found in human breast cancer. Although its role as a mitogenic growth factor capable of inducing cellular proliferation in monolayer culture is generally accepted, its role in generating or maintaining the malignant phenotype in human cancer is entirely unknown.
That TGFa may play an important role in the generation or maintenance of the malignant phenotype of breast cancer is suggested by its regulation by estrogen. While estrogen promotes the growth of MCF-7 cells in vitro and is required for tumor formation in vivo, the mechanism by which estrogen acts has never been fully understood. We and others have shown that estrogen regulates the level of a number of mRNA species and proteins, including the pS2 mRNA (38) , the mitogenic 52 kDa protein (39), a 24 kDa protein (40) , an IGF-l-related protein (41), a 39 kDa protein (42) , and TGFa (43) . For none of these has a physiological role in breast cancer in vivo been clearly elucidated, but all have been proposed as intermediaries of estrogen action.
Estrogen regulates the secretion of TGFa in human breast cancer cells. This regulation occurs, at least in part, by regulation of mRNA levels. An increased level of 4.8 kb TGFa mRNA is seen shortly after addition of physiological concentrations of estrogen to breast cancer cell lines deprived of estrogen. Evidence that this estrogen regulation of TGFa occurring in vitro may occur in vivo is provided by demonstration that withdrawal of estrogen from MCF-7 xenografts results in a decline in TGFa mRNA levels. Similar in vitro and in vivo demonstrations of TGFa regulation have been previously reported in primary estrogen-dependent carcinogen-induced rat mammary tumors (44) .
Because breast cancer cells secrete TGFa, respond to TGFa or EGF, and contain EGF/TGFa receptors, an autocrine hypothesis can be proposed in which the cell secretes TGFa, which acts through its own cell surface receptor to stimulate growth (29) . Partial confirmation of this postulated mechanism has been achieved by the inhibition of anchorage-independent MCF-7 colony formation with anti-TGFa antibodies, and the reversal of estrogen-stimulated anchorage-dependent MCF-7 cell growth by anti-EGF receptor antibodies. Thus, inhibition of cell growth can be achieved by addition of antibodies against either the ligand or its receptor. Such inhibition suggests interruption of an autocrine loop important for the growth of these cells. Because the growth inhibition is incomplete, involvement of other growth factors in the proliferation of these cells is implied. Estrogen regulation of TGFa production in estrogen-responsive breast cancer suggests that hormonal control can be exerted on the autocrine regulation of cellular growth.
In Northern blots, the previously described 4.8 kb TGFa mRNA is seen (31 -33) as well as hybridization with a novel 1.6 kb species. The significance of the 1.6 kb mRNA is unknown. Both species are also seen in poly(A) + enriched RNA from human primary breast cancers. The expression of these 4.8 and 1.6 kb mRNAs are associated with the presence of a high mol wt form of secreted TGFa in the MCF-7 cell line. Although multiple intermediate-sized TGFa polypeptide species have been described as processing products derived from a common glycosylated and palmitoylated high mol wt precursor of 18 k encoded by the cloned human TGFa gene (45) , none of these species approximates the multiple 30 k apparent mol wt TGFa species de-scribed in these studies. The structures of both this high mol wt form of TGFa and the 1.6 kb mRNA are subjects requiring further study.
TGFa mRNA is detectable in approximately 70% of primary human breast cancers, and is present in exceedingly high levels in some of these. Our studies with (28) Estrogen receptor (ER) and progesterone receptor (PR) data were available in 36 of the 40 primary human breast tumors analyzed for TGFa mRNA expression. Samples were scored as positive if they contained levels of TGFa mRNA by slot blot analysis above that of the negative control, Hs578T. This determination was made using the area under the peak seen by densitometric scanning ER and PR values obtained from patient medical records were defined as positive if greater than 10 fm/mg cytosolic protein.
several human breast cancer cell lines suggest that a correlation exists between the levels of TGFa mRNA and the concentration of TGFa released into the conditioned medium. Similarly, in the estrogen induction studies the degree of enhancement of TGFa mRNA is well correlated with observed alterations in TGFa protein levels. By inference, a majority of human primary tumors can be expected to synthesize TGFa protein. A previous study using detergent extracts of 22 primary breast carcinomas for RIA found detectable levels of TGFa in all samples assayed (3). Highest levels were found in estrogen receptor positive tumors, although the number analyzed was too few to be statistically significant. Expression of TGFa mRNA did not show any correlation with the presence of estrogen or progesterone receptor in the 40 tumors examined in the present study. However, a previous analysis of a more limited sample of 15 human breast tumors had noted that 75% of estrogen receptor and progesterone receptor positive tumors contained TGFa mRNA while only 29% of the TGFa mRNA negative tumors were of this phenotype (46) . In contrast to these findings in human tumors, carcinogen-induced estrogen-independent transplantable rat mammary tumors are reported to contain no detectable TGFa mRNA (44) . Whether this difference is due to the human vs. rodent system or to some other selection bias, is unknown. The variability of TGFa expression implies that there can be differences in responsiveness or sensitivity to autocrine reg- ulation and involvement of other pathways of growth regulation among human breast cancers. However, the presence of TGFa as a mitogenic polypeptide, its regulation by estrogen in hormone-dependent systems, and its frequent expression in malignant breast tissue suggest that TGFa is playing a role in either the genesis or maintenance of human breast cancer.
MATERIALS AND METHODS
Cell Lines
Cell lines from the following sources were used: MCF-7 (80th passage), originally obtained from the Michigan Cancer Foundation (47) (49) . Subsequently cells were plated in 5% CCS in IMEM lacking the pH indicator phenol red, which is a weak estrogen (50) . For determination of estrogen effects, pairs of flasks were treated with 10~8 M 170-estradiol or the vehicle, 0.1% ethanol.
Tumors
Primary human breast tumors from 40 female patients were dissected from surgical specimens, frozen in dry ice, and stored at -7 0 C until use.
Conditioned Medium Collections
Conditioned medium collections were carried out as previously described (2). The medium was concentrated 100-fold in an Amicon ultrafiltration cell (YM 5 membrane) (Amicon, Danvers, MA) and used directly in the NRK colony forming assay which was performed as previously described (2) . For radioreceptor studies, the medium was acidified with 4% (vol/vol) acetic acid after addition of 10" 7 M pepstatin, passed through a Waters SEP-PAK C-18 reverse phase cartridge, and washed with 4% acetic acid. The EGF-receptor competing material was quantitively eluted with 50% acetonitrile (Fisher Scientific, Pittsburgh, PA) (3).
EGF RRAs
A431 membranes were prepared according to the method of Kimball and Warren (51) . The cells were disrupted under nitrogen, and the nuclei and organelles pelleted by low speed centrifugation. The membranes were then pelleted by centrifugation at 35,000 rpm for 1 h and resuspended in 20 mM HEPES buffer. Membranes were plated into 96-well plates and allowed to dry overnight at 37 C before use. Standard binding competition studies were performed using [ 125 I]EGF (SA, 100 fiC\lng; 50,000 cpm/assay). A standard curve of 0.2-50 ng unlabeled mouse (receptor grade, Collaborative Research, Waltham, MA) EGF was constructed. The SEP-PAK acetonitrile fractions were lyophilized and reconstituted in 4 mM HCI (0.5 ml/50 ml conditioned media). After incubation of the labeled EGF and 100-/il samples for 2 h at 21 C in Dulbecco's modified Eagle's medium (DMEM) (GIBCO) containing 50 mM HEPES, 0.1% BSA, the wells were washed, cut from the plate, and counted in a 7-spectrometer. EGF competing activity was computed using a Hewlett-Packard RIA program (52) .
RIA
RIAs were performed using polyclonal rabbit antirat TGFa antibody and 125 l-rat TGFa (Biotope, Inc., Seattle, WA), according to manufacturer's instructions. The antibody used was raised against a 17-amino acid synthetic peptide from the COOH-terminus of mature rat TGFa (53) .
Metabolic Labeling and Immunoprecipitation of 3S SLabeled Conditioned Medium
Confluent 100-mm culture dishes of MCF-7 cells were washed with serum-free DMEM and incubated for 2 hours in cysteinefree DMEM containing 10 iig/m\ each of bovine pancreatic insulin and human transferrin with 1 % dialyzed FBS. Cells were labeled 18 h with 100 /xCi/ml ^S-cysteine (Amersham Corp., Arlington Heights, IL; 1250 Ci/mmol). The labeled medium was then collected, centrifuged at 10,000 rpm, and chromatographed over a Sephadex G-25 column in distilled water to remove unincorporated 35 S-cysteine. Fractions containing radioactive protein were lyophilized and reconstituted in 1 ml radioimmunoprecipitation (RIPA) buffer containing 1 % Triton X-100, 0.5% deoxycholate, 100 mM NaCI, 1 mM EDTA, 0.1 mM phenylmethylsufonyl fluoride (Sigma), 50 Mg/ml leupeptin, and 50 tig/m\ aprotinin in 10 mM Na(P04), pH 8.0. After reduction with 40 mM dithiothreitol, 400 n\ reconstituted labeled conditioned medium was incubated in the absence or presence of 250 ng human TGFa with 50 n\ polyclonal goat antihuman TGFa IgG (Biotope Inc.) covalently coupled to Sepharose 4B at a concentration of 5 mg IgG/ml gel for 48 h at 4 C. The immunoprecipitates were washed five times in RIPA buffer, and the bound material was eluted from the antibody-Sepharose matrix by incubation with 1 ml 1 N acetic acid for 30 min at 60 C. The eluted radioactivity was lyophilized, reconstituted in sample buffer containing SDS, and run on a 15% discontinuous SDS-polyacrylamide gel. The synthetic TGFa used in competition was prepared as previously described (54) .
MCF-7 Tumor Formation in Nude Mice
Two x 10 7 MCF-7 cells were injected sc into twenty 5-weekold nude Balb/C mice with implanted 10 mg 170-estradiol pellets. After 3 weeks, tumors were harvested from control animals; and then 18 h, 3 days, and 10 days after removal of the estrogen pellets from the experimental animals. Tumors were stored at -7 0 C before RNA extraction.
MCF-7 Cloning and Monolayer Growth Experiments
Two x 10
4 MCF-7 cells were plated in DMEM containing 0.4% Bacto-agar (Difco, Detroit, Ml) and 10% FBS over a bottom layer containing 0.8% agar in 35-mm tissue culture dishes (Costar, Cambridge, MA). Purified polyclonal rabbit antihuman TGFa IgG which was isolated by protein A-sepharose chromatography of rabbit antiserum raised against synthetic human TGFa (54) was used in varying dilutions to test for inhibition of MCF-7 colony formation in agar. Colonies were incubated for 14 days, then stained with nitrobluetetrazolium (NBT), and counted. The antibody is specific for human TGFa, and does not recognize mouse or human EGF (Tarn, J., and C. K. Chang, unpublished data). Purified rabbit IgG (Cappel Laboratory) was used as a control. Recombinant human TGFa (31) used for antibody neutralization was a gift from Rik Derynck (Genentech, Inc.).
For monolayer growth studies of estrogen-induced MCF-7 proliferation, purified mouse monoclonal antihuman EGF re-ceptor antibody was used (35) . This antibody has been previously characterized to be a pure antagonist of the EGF receptor; it blocks EGF-stimulated proliferation of human fibroblasts in monolayer. Details of the procedure used in blockade of estrogen-induced MCF-7 growth with this antibody are in the footnote of Table 2 . Data representative of four separate experiments are shown.
TGFa Hybridization Probes
A 1.3 kb cDNA probe encoding the precursor for mature human TGFa (31) ligated into the plasmid SP65, a gift from Rik Derynck, was used to make a synthetic riboprobe with SP6 polymerase (Promega Biotech, Madison, Wl). Alternatively, the human TGFa cDNA insert was obtained by restriction digest of plasmid pTGF-CI with EcoRI, agarose gel purified, and used for nick translation. A 1.7 kb 0-actin cDNA cloned into pGEM3 was used to make a riboprobe with SP6 polymerase (55) .
RNA Extraction, Electrophoresis, and Filter Preparation
Total cellular RNA was extracted from cells by homogenizing in guanidine isothiocyanate followed by centrifugation over a cesium chloride cushion. RNA from tumor samples was extracted after pulverization of frozen samples and homogenization in guanidine isothiocyanate. Poly(A) + mRNA was eluted in 10 rm/i Tris after passing total cellular RNA over an oligo(DT) cellulose (Pharmacia, Piscataway, NJ) column equilibrated with 10 mM Tris-0.5 M NaCI, pH 8.0. After precipitation in ethanol (66% vol/vol) and 0.1 M NaAc, both total and poly(A) + selected RNA were resuspended in 10 mM Tris-1 mM EDTA buffer, and separated on 1% agarose, 6% formaldehyde gels. Electrophoresis was carried out at 20 V over 14-16 h in 5 mM NaAc, 1 mM EDTA, 20 mM 3-[N-Morpholino]propanesulfonic acid (MOPS) (Sigma), pH 7.0. Gels were stained with 2 M g/ml ethidium bromide to allow inspection of the quantity and quality of RNA. Only gels containing comparably loaded RNA samples of the highest quality were used for Northern transfer. RNA gels were subjected to partial alkaline hydrolysis in 50 mM NaOH, 10 mM NaCI, followed by neutralization with 0.1 M Tris HCI (pH 7.5) and equilibration with 10x SSC (1.5 M NaCI, 0.15 M trisodium citrate). Northern transfer of RNA to nitrocellulose was by capillary blot. Nitrocellulose filters used for slot blot preparation were presoaked in 10x SSC. All filters were then baked for 2 h at 80 C under vacuum.
Hybridizations
Synthetic riboprobe was prepared by SP6 polymerase transcription using uridine 5'-triphosphate, tetra (triethylammonium) salt [a-32 P] (SA, 3000 Ci/mmol) (New England Nuclear, Boston, MA). The DNA template was linearized with Hind\\\. Filters were prehybridized for 4 h at 55 C in 50% formamide (Fluka, Buchs, Switzerland) 5x Denhardt's, 5x SSC, 0.1% SDS, and 200 ng/ml salmon sperm DNA (Sigma), and hybridized for 16-18 h in the same buffer with 2 x 10 6 cpm/ml labeled riboprobe. Filters were washed twice for 30 min with 1 x SSC, 0.1% SDS heated to 68 C, and twice for 30 min with 0.1 x SSC, 0.1 % SDS in a 70 C water bath. After hybridization, autoradiography was performed using Kodak XAR-5 film exposed for 2-4 days at -7 0 C.
For cDNA insert probes, deoxycytidine 5' triphosphate, tetra (triethylammonium) salt, [a 32 P] (SA, 3000 Ci/mmol) (New England Nuclear) was incorporated into the human TGFa cDNA probe pTGF-CI using the nick translation kit from New England Nuclear. Prehybridization and hybridization were performed for 24 h at 42 C in the same buffers as for the riboprobe labeling with 1 x 10 6 cpm/ml nick translated DNA. In addition to ethidium bromide staining of gels to ensure comparable loading, filters were routinely hybridized to a 0-actin probe to demonstrate equivalent levels of mRNA. In some of the estrogen-induction experiments where ethidium bromide staining clearly demonstrated comparability of loading, 0-actin hybridization demonstrated variability. Alterations were felt to be due to limited regulation of j3-actin message by estrogen and/or cell growth. Densitometric analysis was performed to quantify differences in levels of TGFa mRNA.
